Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vitamin D and Health Outcomes

Vitamin D and Health Outcomes Opinion EDITORIAL Then Came the Randomized Clinical Trials Anika Lucas, MD; Myles Wolf, MD, MMSc Not long ago, vitamin D was riding high. Beyond its role in ary outcomes included time to the composite outcome of 40% calcium homeostasis and bone health, animal studies reduction in eGFR or ESKD or death, and change in albumin- uria from baseline to year 5. linked vitamin D deficiency to numerous chronic illnesses including hypertension, dia- At baseline, the mean eGFR was 85.8 mL/min/1.73 m ,16% betes, autoimmunity, and of participants had eGFR less than 60 mL/min/1.73 m , and 9% Related article page 1899 malignancy. Corroborating had microalbuminuria greater than 30 mg/g creatinine. The human observational stud- mean 25-hydroxyvitamin D level was 29.7 ng/mL, and 50% of ies reported associations between vitamin D deficiency and study participants had 25-hydroxyvitamin D levels less than increased risks of hypertension, diabetes, cardiovascular 30 ng/mL; only 16% had levels less than 20 ng/mL, which is disease, autoimmunity, and cancer. The lay press seized on considered inadequate. Self-reported adherence to the inter- this chorus of observational studies, testing of serum ventions was excellent and corroborated by substantial dif- 25-hydroxyvitamin D levels proliferated, and supplementa- ferences in serum http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Vitamin D and Health Outcomes

Lucas, Anika; Wolf, Myles
JAMA , Volume 322 (19) – Nov 19, 2019
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/vitamin-d-and-health-outcomes-DFUSDe0vMr

References (16)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.17302
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Then Came the Randomized Clinical Trials Anika Lucas, MD; Myles Wolf, MD, MMSc Not long ago, vitamin D was riding high. Beyond its role in ary outcomes included time to the composite outcome of 40% calcium homeostasis and bone health, animal studies reduction in eGFR or ESKD or death, and change in albumin- uria from baseline to year 5. linked vitamin D deficiency to numerous chronic illnesses including hypertension, dia- At baseline, the mean eGFR was 85.8 mL/min/1.73 m ,16% betes, autoimmunity, and of participants had eGFR less than 60 mL/min/1.73 m , and 9% Related article page 1899 malignancy. Corroborating had microalbuminuria greater than 30 mg/g creatinine. The human observational stud- mean 25-hydroxyvitamin D level was 29.7 ng/mL, and 50% of ies reported associations between vitamin D deficiency and study participants had 25-hydroxyvitamin D levels less than increased risks of hypertension, diabetes, cardiovascular 30 ng/mL; only 16% had levels less than 20 ng/mL, which is disease, autoimmunity, and cancer. The lay press seized on considered inadequate. Self-reported adherence to the inter- this chorus of observational studies, testing of serum ventions was excellent and corroborated by substantial dif- 25-hydroxyvitamin D levels proliferated, and supplementa- ferences in serum

Journal

JAMA – American Medical Association

Published: Nov 19, 2019

There are no references for this article.